Amarin (United Kingdom) Drug Class: Fatty Acid Mechanism/Technology: AMR101 (previously Miraxion) is a semi-synthetic, ultra pure (~97%) derivative of (all-cis)-5,8,11,14,17-eicosapentaenoic acid (ethyl-EPA). It is a long chain highly unsaturated fatty acid. AMR101 is in Phase III trials for HD. Action of AMR101 is believed to involve (1) replenishment of the lipid bi-layer potentially restoring neuronal function, (2) reducing the over production of enzymes (PLA2) associated with apoptosis and (3) stabilizing mitochondrial integrity by acting on specific signal transduction pathways and changing cellular energy metabolism Primary Indication: Huntington's Disease Stage: Phase III
